Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 7 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
61 41.5 months Follicular lymphoma 5 Biologic therapy
University of Bologna Italy 10/2012
Treatment Details: Patients: This phase 3 study involved follicular lymphoma patients who were divided into two separate treatment groups. Group A consisted of 103 patients with a median age of 61 years and
 
62 41.3 months Metastatic breast cancer 4 Hormone
University of California Irvine Medical Center United States 8/2012
Treatment Details: Patients: This study involved postmenopausal women with previously untreated metastatic breast cancer who were divided into two separate treatment groups. Group A consisted of 345 patients
 
63 41.2 months Operable hepatocellular carcinoma Chemotherapy
Queen Elizabeth Hospital Hong Kong SAR, PRC 4/2003
Treatment Details: Patients: Forty patients with hepatocellular (liver) carcinoma who had already undergone curative resection were involved in this study. Patients were divided into two groups: Group 1 rece
 
64 41.0 months Metastatic breast cancer 4 Chemotherapy
Korea University Guro Hospital Korea 2/2009
Treatment Details: Patients: This study involved thirty-two women with recurrent metastatic breast cancer. The median age was 49 years, ranging from 33 to 64. All had received prior treatment with an anthrac
 
65 41.0 months Metastatic breast cancer 5 Chemotherapy
Aristotle University of Thessaloniki School of Medicine Greece 5/2009
Treatment Details: Patients: This phase 2 study involved 416 women with metastatic breast cancer. They ranged in age from 27 to 84 years old. The majority (over 75%) were postmenopausal. Treatment: Pati
 
66 40.8 months Ovarian cancer (no evidence of disease) 4 Biologic therapy
Vaccine Branch, CCR, NCI United States 9/2011
Treatment Details: Patients: This study involved women with ovarian cancer and overexpression of the p53 gene. It was noted that there was no evidence of disease in the patients at the beginning of the study
 
67 40.4 months Mucosal melanoma 4 Immunotherapy
Peking University Cancer Hospital & Institute China 8/2013
Treatment Details: Patients: This phase 2 study involved mucosal melanoma patients who were divided into two separate treatment groups. Group A consisted of 63 patients with a median age of 55 years; 39.7% w
 
68 40.2 months Advanced ovarian cancer 4 Chemotherapy
Oslo University Hospital Norway 10/2012
Treatment Details: Patients: This phase 3 study involved previously untreated advanced ovarian cancer patients who were divided into two separate treatment groups. Group A consisted of 445 patients with a me
 
69 40.2 months Recurrent Ovarian Cancer 5 Chemotherapy
University Medical Center Hamburg-Eppendorf Germany 2/2015
Treatment Details: Patients: This phase 3 study involved platinum-sensitive, recurrent ovarian cancer patients who were divided into two separate treatment groups. Group A had 131 patients with a median age o
 
70 39.0 months Metastatic Breast Cancer 5 Biologic therapy
Chemotherapy
Institut Universitaire de Cancerologie Université Pierre et Marie Curie France 11/2014
Treatment Details: Patients: This phase 3 study involved HER2-negative metastatic breast cancer patients who were divided into two separate treatment groups. There were 94 patients in group A with a median ag
 
Page 7 of 187  | Previous Page  | Next Page